Group 1 - The core point of the article is that on December 9, shareholders of Sihuan Pharmaceutical (01530) deposited shares into Standard Chartered Bank (Hong Kong), with a total market value of HKD 3.071 billion, representing 4.32% of the company [1] - Sihuan Pharmaceutical announced the issuance of 105 million shares on December 9, 2025, based on a placement agreement signed on December 2, 2025 [1]

从连续性进行统计， 有1只股获南向资金连续3天以上净买入，连续净买入天数较多的有小米集团-W， 连续净买入天数分别为8天。以其间净买入金额统计，净买入金额最多的是小米集团-W，合计净买入为 67.79亿港元。（数据宝） | 代码 | 简称 | 成交金额 | 成交净买入 | 今日涨跌幅（%） | | --- | --- | --- | --- | --- | | | | （万港元） | （万港元） | | | 00700 | 腾讯控股 | 491742.93 | 87764.01 | -0.41 | | 01810 | 小米集团-W | 452398.77 | 53999.37 | -3.10 | | 09988 | 阿里巴巴-W | 735167.81 | 42544.69 | -1.63 | | 01288 | 农业银行 | 111432.77 | 30679.90 | 0.88 | | 01347 | 华虹半导体 | 161787.89 | 25044.14 | -5.41 | | 01801 | 信达生物 | 50561.70 | 17926.38 | -1.40 | | 06869 | 长飞光纤光缆 ...

Market Overview - On December 9, the Hang Seng Index fell by 1.29%, closing at 25,434.23 points, with a net inflow of HKD 531 million through the southbound trading channel [1][2] - The total trading volume for the southbound trading on December 9 was HKD 96.695 billion, with a net buying of HKD 531 million [1] Southbound Trading Details - In the Shanghai Stock Exchange southbound trading, the total trading amount was HKD 60.3 billion, with a net selling of HKD 35.2 million; in the Shenzhen Stock Exchange, the total trading amount was HKD 36.396 billion, with a net buying of HKD 88.3 million [1] - The top active stocks in the southbound trading included Alibaba-W, Xiaomi Group-W, and Tencent Holdings, with trading amounts of HKD 41.15 billion, HKD 33.21 billion, and HKD 29.30 billion respectively [1][2] Stock Performance - In terms of net buying, Tencent Holdings led with a net buying amount of HKD 112.56 million, despite a closing price drop of 0.41% [1][2] - The stock with the highest net selling was Pop Mart, with a net selling amount of HKD 43.83 million, closing down by 5.04% [1][2] - In the Shenzhen Stock Exchange, Alibaba-W had a trading amount of HKD 32.37 billion, followed by Tencent Holdings and SMIC with amounts of HKD 19.87 billion and HKD 15.03 billion respectively [2] Summary of Active Stocks - The top ten active stocks in the southbound trading included: - Alibaba-W: Trading amount of HKD 411.5 million, net buying of HKD 83.45 million, down by 1.63% - Xiaomi Group-W: Trading amount of HKD 332.1 million, net buying of HKD 156.18 million, down by 3.10% - Tencent Holdings: Trading amount of HKD 293.0 million, net buying of HKD 112.56 million, down by 0.41% - Pop Mart: Trading amount of HKD 188.0 million, net selling of HKD 43.83 million, down by 5.04% [2]

Group 1 - The company, Sanofi Pharmaceutical (01530), announced the issuance of 105 million shares on December 9, 2025, based on a placement agreement signed on December 2, 2025 [1]

Core Viewpoint - The company, 3SBio Inc. (01530), announced the issuance of 105 million shares on December 9, 2025, based on a placement agreement signed on December 2, 2025 [1] Group 1 - The share issuance is part of a strategic move to raise capital [1] - The agreement for the share placement was finalized just a week prior to the issuance date [1]

Core Viewpoint - Sanofi Pharmaceutical (01530.HK) has successfully completed a placement agreement, issuing a total of 105,169,500 shares at a price of HKD 29.62 per share, representing approximately 4.14% of the enlarged issued share capital [1] Group 1: Placement Details - The placement was completed on December 9, 2025, with shares allocated to no fewer than six subscribers [1] - The net proceeds from the placement, after deducting commissions and related expenses, amount to approximately HKD 3.087 billion [2] Group 2: Use of Proceeds - Approximately 80% or HKD 2,469.47 million of the net proceeds will be allocated for research and development expenses, which include: - Advancing clinical studies for innovative drugs in China and the U.S. to accelerate pipeline progress, including but not limited to drugs 705 (PD1/HER2), 706 (PD1/PDL1), 008 (B7H3/IL15), 59 (MUC17/CD3/CD28), 626 (BDCA2), and 627 (TL1A) [2] - Supporting the expansion of indications for commercialized drugs or clinical trials outside of China to enhance product value and market coverage, including but not limited to TPO and EPO [2] - Building global infrastructure and supporting facilities [2] - Approximately 20% or HKD 617.37 million will be used for working capital and other general corporate purposes to support the group's ongoing operations and strategic plans [2]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 本 公 告 僅 供 參 考，並 不 構 成 收 購、購 買 或 認 購 本 公 司 證 券 的 邀 請 或 要 約。 本公告及其任何副本均不得直接或間接在美國或任何其他可能非法發佈或分發的司法管轄區發佈或分 發。本 公 告 並 不 構 成 或 組 成 於 美 國 購 買 或 認 購 證 券 的 任 何 要 約 或 招 攬 的 一 部 分。本 公 告 所 述 證 券 並 未 亦 不會根據1933年美國證券法（「美國證券法」）登 記，亦 不 得 在 美 國 提 呈 發 售 或 出 售，除 非 根 據 美 國 證 券 法 作 出 登 記 或 獲 豁 免 登 記 或 為 毋 須 根 據 美 國 證 券 法 作 出 登 記 之 交 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 三生製藥（「本公司」） 呈交日期： 2025年12月9日 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： (註7) (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； (vi) 確實所有權文件按照發行、出售或轉讓條款的規定經已發送/現正準備發送/正在準備中並將會發送。 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | ...

Core Viewpoint - The Hong Kong stock market for innovative drugs continues to decline, with the Hang Seng Index falling below the six-month moving average, indicating ongoing adjustments in the sector [1][3]. Market Performance - On December 9, the Hong Kong innovative drug ETF (520880) experienced a decline of 1.99%, marking two consecutive days of losses, with a trading volume of 283 million yuan [1]. - Major stocks within the ETF saw significant declines, including Kangfang Biotech down 4%, Sanofi Biotech down 3.63%, and Innovent Biologics down 1.4% [1]. Investment Opportunities - Analysts suggest that the current market conditions may present a favorable opportunity for long-term investment in core innovative drug assets, as the index has retraced over 18% since early September, indicating a sufficient adjustment and risk release [3]. - There are positive signals in the funding landscape, with over 56 million yuan net subscriptions for the innovative drug ETF on the previous day, the highest in nearly a month, indicating strong buying interest [4]. Policy Developments - The 2025 National Medical Insurance Drug List has successfully added 114 new drugs, including 50 innovative drugs, with an overall success rate of 88%, significantly higher than the 76% in 2024 [5]. Business Development - Kelun-Biotech has granted exclusive rights to Crescent for the development of ADC drug SKB105 outside Greater China, along with exclusive rights for CR-001 bispecific antibody in Greater China, which includes an upfront payment of 80 million USD and potential milestone payments of up to 1.25 billion USD [6]. - Analysts recommend focusing on innovative drug companies with rich pipeline layouts, high potential single products, and leading technology platforms [6]. ETF Characteristics - The Hong Kong innovative drug ETF (520880) has a significant concentration in leading companies, with the top ten holdings accounting for over 72% of the index, showcasing the strength of the innovative drug sector [7]. - The ETF has a total market value of 2.142 billion yuan and has the highest liquidity among similar ETFs, with an average daily trading volume of 458 million yuan since its inception [7].

Core Insights - On December 9, 2025, Alibaba-W (09988), Xiaomi Group-W (01810), and Tencent Holdings (00700) were the top three companies by trading volume in the southbound trading of the Stock Connect, with trading amounts of 4.115 billion, 3.321 billion, and 2.930 billion respectively [1] - In the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), Tencent Holdings (00700), and SMIC (00981) led the trading volume, with amounts of 3.237 billion, 1.987 billion, and 1.503 billion respectively [1] Southbound Trading Highlights - **Top Active Companies in Southbound Trading (Shanghai-Hong Kong Stock Connect)** - Alibaba-W (09988): Trading amount of 4.115 billion, net inflow of 83.45 million [2] - Xiaomi Group-W (01810): Trading amount of 3.321 billion, net inflow of 156 million [2] - Tencent Holdings (00700): Trading amount of 2.930 billion, net inflow of 1.126 billion [2] - SMIC (00981): Trading amount of 2.806 billion, net outflow of 133 million [2] - Pop Mart (09992): Trading amount of 1.880 billion, net outflow of 438 million [2] - **Top Active Companies in Southbound Trading (Shenzhen-Hong Kong Stock Connect)** - Alibaba-W (09988): Trading amount of 3.237 billion, net inflow of 342 million [2] - Tencent Holdings (00700): Trading amount of 1.987 billion, net outflow of 248 million [2] - SMIC (00981): Trading amount of 1.503 billion, net inflow of 14.69 million [2] - Xiaomi Group-W (01810): Trading amount of 1.203 billion, net inflow of 384 million [2] - Pop Mart (09992): Trading amount of 1.016 billion, net outflow of 136 million [2]